aMoon Fund

Lutris Pharma is a biopharmaceutical company based in Tel Aviv-Yafo, Israel, focused on developing innovative therapies to enhance the effectiveness of anti-cancer treatments. Established in 2015, the company has created a proprietary small molecule drug known as LUT014, which acts as a topical B-Raf inhibitor. This drug facilitates the use of epidermal growth factor receptor (EGFR) inhibitors while minimizing the common cutaneous side effects typically associated with such treatments. By addressing these side effects, Lutris Pharma aims to improve both the efficacy of anti-cancer therapies and the overall quality of life for patients undergoing treatment with EGFR inhibitors.

Air Doctor Ltd. operates an online marketplace that connects travelers with verified healthcare professionals in various locations. Founded in 2016 and based in Motza Illit, Israel, the platform allows users to search for and schedule appointments with doctors, dentists, emergency clinics, pharmacies, and other healthcare specialists. By providing access to practitioner profiles and patient reviews, Air Doctor simplifies the process of obtaining medical care abroad, ensuring that users can find professionals who speak their language and meet their specific needs. This service aims to enhance the experience of travelers by making healthcare access straightforward and efficient in unfamiliar destinations.

Ibex Medical Analytics Ltd is a company based in Tel Aviv, Israel, that specializes in developing artificial intelligence-based systems for cancer diagnosis. Its flagship product, the Ibex Second Read system, operates alongside human pathologists, analyzing cases in parallel to identify discrepancies between the pathologist's diagnoses and its own analysis. By leveraging advancements in AI, data science, image analysis, and machine learning, Ibex aims to enhance clinical decision-making and streamline pathology laboratory workflows. The technology utilizes digitized glass slides and electronic medical records to uncover underlying patterns and extract clinical insights, ultimately enabling pathologists to provide rapid, objective, and accurate diagnoses. Through its innovative approach, Ibex strives to improve patient outcomes and quality of life in the field of cancer care.

Nectin Therapeutics Ltd. is a biotechnology company founded in 2017 and based in Jerusalem, Israel. The company specializes in the development of novel monoclonal antibodies that target members of the Nectin family of receptors and ligands, which play significant roles in immune checkpoint mechanisms relevant to cancer immunotherapy. Nectin Therapeutics focuses on creating therapies for both solid and hematological malignancies by designing antibodies that can bypass the inhibitory pathways used by tumors, thereby enhancing the ability of immune cells to effectively eliminate cancer cells. Through its innovative approach, the company aims to improve patient outcomes in the fight against cancer.

Ibex Medical Analytics Ltd is a company based in Tel Aviv, Israel, that specializes in developing artificial intelligence-based systems for cancer diagnosis. Its flagship product, the Ibex Second Read system, operates alongside human pathologists, analyzing cases in parallel to identify discrepancies between the pathologist's diagnoses and its own analysis. By leveraging advancements in AI, data science, image analysis, and machine learning, Ibex aims to enhance clinical decision-making and streamline pathology laboratory workflows. The technology utilizes digitized glass slides and electronic medical records to uncover underlying patterns and extract clinical insights, ultimately enabling pathologists to provide rapid, objective, and accurate diagnoses. Through its innovative approach, Ibex strives to improve patient outcomes and quality of life in the field of cancer care.

MDClone Ltd. is a company that specializes in software development for analyzing medical records. Founded in 2016 and based in Beersheba, Israel, MDClone has created a platform that generates synthetic medical records for fictitious patients, thus mitigating the risk of disclosing actual patient data. This innovative platform, known as ADAMS, provides a self-service analytics environment that facilitates exploration and collaboration across the healthcare ecosystem. By enabling researchers and healthcare organizations to examine disease behaviors, treatment efficacy, and operational efficiencies, MDClone supports the advancement of medical research and improves patient outcomes while ensuring the protection of sensitive medical information. The company serves a diverse clientele that includes major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

Omada Health, Inc. is a digital healthcare company that specializes in developing online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, California, with an additional office in Atlanta, Georgia, Omada focuses on preventing conditions such as prediabetes, diabetes, hypertension, and heart disease. The company provides personalized digital health programs that cater to the unique needs of individuals, utilizing professional health coaching, connected health devices, and real-time data to facilitate meaningful health improvements. Omada is recognized as the largest provider of the National Diabetes Prevention Program, empowering individuals to engage actively in their health and achieve sustainable lifestyle changes. The platform also addresses behavioral health issues, including anxiety and depression, further supporting individuals in their overall wellness journey.

DayTwo Ltd. is a precision nutrition company based in Tel Aviv-Yafo, Israel, that focuses on leveraging gut microbiome analysis to provide tailored health solutions for metabolic diseases such as diabetes, prediabetes, clinical obesity, and non-alcoholic fatty liver disease (NAFLD). Founded in 2015, DayTwo utilizes a web-based platform that offers personalized dietary recommendations through its innovative Food Prescriptions™, which are designed to help individuals manage their blood sugar levels and improve overall health. By sequencing gut microbiomes, the company identifies how different foods affect each person, allowing for customized nutrition plans. DayTwo's virtual care model is supported by Certified Diabetes Care and Education Specialists and Registered Dietitians, who engage with patients through a smartphone application to track progress and ensure adherence to the dietary recommendations.

Ibex Medical Analytics Ltd is a company based in Tel Aviv, Israel, that specializes in developing artificial intelligence-based systems for cancer diagnosis. Its flagship product, the Ibex Second Read system, operates alongside human pathologists, analyzing cases in parallel to identify discrepancies between the pathologist's diagnoses and its own analysis. By leveraging advancements in AI, data science, image analysis, and machine learning, Ibex aims to enhance clinical decision-making and streamline pathology laboratory workflows. The technology utilizes digitized glass slides and electronic medical records to uncover underlying patterns and extract clinical insights, ultimately enabling pathologists to provide rapid, objective, and accurate diagnoses. Through its innovative approach, Ibex strives to improve patient outcomes and quality of life in the field of cancer care.

Nectin Therapeutics Ltd. is a biotechnology company founded in 2017 and based in Jerusalem, Israel. The company specializes in the development of novel monoclonal antibodies that target members of the Nectin family of receptors and ligands, which play significant roles in immune checkpoint mechanisms relevant to cancer immunotherapy. Nectin Therapeutics focuses on creating therapies for both solid and hematological malignancies by designing antibodies that can bypass the inhibitory pathways used by tumors, thereby enhancing the ability of immune cells to effectively eliminate cancer cells. Through its innovative approach, the company aims to improve patient outcomes in the fight against cancer.

Curesponse is a diagnostics company based in Tel Aviv-Yafo, Israel, founded in 2017. It specializes in developing a three-dimensional tissue culture system that models cancer growth and drug response. This innovative platform allows patients and clinicians to send tumor samples for testing, preserving the cancer tissue architecture, including vasculature and immune components. By accurately reflecting the cancer growth found in the body, Curesponse's technology enhances personalized cancer medicine, moving beyond traditional genomic predictions to assess functional responses in living patient cells. The company's goal is to match the appropriate drug to an individual’s specific tumor type, ultimately improving patient survival rates and reducing unnecessary medical interventions.

Igentify Ltd is an Israeli company specializing in preventive healthcare through genomic products and services. Founded in 2016 by Galit Delmar and Yagil Tzur, Igentify is headquartered in Haifa. The company focuses on enhancing access to genomic information for clinicians, laboratories, and patients through its end-to-end digital genetic platform. One of its key offerings is FamilyFirst, an expanded carrier screening designed specifically for the Jewish and Israeli populations. Igentify's platform addresses the increasing demand for genomic medicine by digitizing various processes related to genetic testing, including patient education, consent collection, data analysis, and the delivery of personalized results. This approach aims to streamline and simplify the complexities often associated with genomic healthcare.

MDClone Ltd. is a company that specializes in software development for analyzing medical records. Founded in 2016 and based in Beersheba, Israel, MDClone has created a platform that generates synthetic medical records for fictitious patients, thus mitigating the risk of disclosing actual patient data. This innovative platform, known as ADAMS, provides a self-service analytics environment that facilitates exploration and collaboration across the healthcare ecosystem. By enabling researchers and healthcare organizations to examine disease behaviors, treatment efficacy, and operational efficiencies, MDClone supports the advancement of medical research and improves patient outcomes while ensuring the protection of sensitive medical information. The company serves a diverse clientele that includes major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

DayTwo Ltd. is a precision nutrition company based in Tel Aviv-Yafo, Israel, that focuses on leveraging gut microbiome analysis to provide tailored health solutions for metabolic diseases such as diabetes, prediabetes, clinical obesity, and non-alcoholic fatty liver disease (NAFLD). Founded in 2015, DayTwo utilizes a web-based platform that offers personalized dietary recommendations through its innovative Food Prescriptions™, which are designed to help individuals manage their blood sugar levels and improve overall health. By sequencing gut microbiomes, the company identifies how different foods affect each person, allowing for customized nutrition plans. DayTwo's virtual care model is supported by Certified Diabetes Care and Education Specialists and Registered Dietitians, who engage with patients through a smartphone application to track progress and ensure adherence to the dietary recommendations.

Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company based in Rehovot, Israel, founded in 2017. The company specializes in developing small molecule therapeutics for rare and aggressive cancers, focusing on genetically defined patient populations. Its lead product candidate is AL101, an intravenous gamma secretase inhibitor currently in Phase II clinical trials for treating recurrent/metastatic adenoid cystic carcinoma in patients with Notch-activating mutations. Additionally, Ayala Pharmaceuticals is developing AL102, an oral gamma secretase inhibitor in Phase I clinical trials for desmoid tumors. The company has a collaboration agreement with Novartis to develop AL102 for multiple myeloma. Ayala's approach involves using bioinformatics and next-generation sequencing to identify and address tumorigenic drivers of cancer, aiming to deliver targeted therapies to underserved patient populations.

Ibex Medical Analytics Ltd is a company based in Tel Aviv, Israel, that specializes in developing artificial intelligence-based systems for cancer diagnosis. Its flagship product, the Ibex Second Read system, operates alongside human pathologists, analyzing cases in parallel to identify discrepancies between the pathologist's diagnoses and its own analysis. By leveraging advancements in AI, data science, image analysis, and machine learning, Ibex aims to enhance clinical decision-making and streamline pathology laboratory workflows. The technology utilizes digitized glass slides and electronic medical records to uncover underlying patterns and extract clinical insights, ultimately enabling pathologists to provide rapid, objective, and accurate diagnoses. Through its innovative approach, Ibex strives to improve patient outcomes and quality of life in the field of cancer care.

Zebra Medical Vision Ltd. is a developer of an advanced imaging analytics platform that enhances the capabilities of healthcare institutions in diagnosing and managing diseases. Founded in 2014 and based in Shefayim, Israel, the company provides clinicians with tools for identifying patients at risk of various conditions and facilitates improved preventative treatment pathways. Its platform features advanced learning and computer vision diagnostic algorithms, catering to both healthcare providers and machine-learning researchers. Zebra Medical Vision has established strategic collaborations with organizations such as USARAD Holdings and TELUS Ventures, and its products have received FDA clearance for use in hospitals worldwide, including locations in Australia, India, Europe, the U.S., and Latin America. The company is recognized for its role in the AI and machine learning landscape, having raised significant funding to support its innovative solutions in medical imaging.

CartiHeal Ltd. is a medical device company based in Kfar Sava, Israel, specializing in the development of innovative solutions for cartilage and bone disorders. Founded in 2009, the company has pioneered a cell-free implant technology known as Agili-C, designed to address focal articular cartilage and osteochondral defects. This off-the-shelf implant promotes the regeneration of true hyaline cartilage and its underlying subchondral bone through a minimally invasive procedure, without the need for cells or growth factors. CartiHeal's Agili-C implant represents a significant advancement in the treatment of cartilage injuries, which can lead to severe pain, disability, and early onset of osteoarthritis if left untreated. By offering a well-tolerated and effective solution, CartiHeal aims to meet a critical need in the field of cartilage repair and regeneration.